(Reuters) - U.S. health regulators on Wednesday approved a pair of GlaxoSmithKline Plc drugs to treat advanced melanoma - the deadliest form of skin cancer - in patients with specific genetic mutations. It also approved a diagnostic test to detect the mutations. The Food and Drug Administration said it approved the drugs, Tafinlar and Mekinist, to be used as single agents and not in combination after the medicines delayed tumor growth in separate clinical trials. ...
via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment